Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 5.0 | 5.0 |
Min SIP Amount | ₹500 | ₹100 |
Expense Ratio | 1.93 | 1.87 |
NAV | ₹431.43 | ₹40.48 |
Fund Started | 04 Jun 1999 | 25 Jun 2018 |
Fund Size | ₹4082.13 Cr | ₹6437.36 Cr |
Exit Load | Exit load of 0.50% if redeemed within 15 days | Exit load of 1% if redeemed within 15 days. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 2.69% | 4.16% |
3 Year | 24.61% | 26.87% |
5 Year | 19.54% | 20.58% |
1 Year
3 Year
5 Year
Equity | 96.05% | 97.10% |
Cash | 3.88% | 2.90% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 11.18% |
Divi's Laboratories Ltd. | 7.26% |
Max Healthcare Institute Ltd. | 5.62% |
Cipla Ltd. | 4.41% |
Lonza Group Ag | 4.05% |
Lupin Ltd. | 4.04% |
Acutaas Chemicals Ltd. | 3.81% |
Fortis Healthcare Ltd. | 3.76% |
Torrent Pharmaceuticals Ltd. | 3.49% |
Jupiter Life Line Hospitals Ltd. | 3.46% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 11.88% |
Dr. Reddy's Laboratories Ltd. | 9.42% |
Divi's Laboratories Ltd. | 8.50% |
Aurobindo Pharma Ltd. | 7.62% |
Cipla Ltd. | 6.61% |
Lupin Ltd. | 5.40% |
Alkem Laboratories Ltd. | 3.98% |
Biocon Ltd. | 3.28% |
Mankind Pharma Ltd. | 2.79% |
Zydus Lifesciences Ltd. | 2.67% |
Name | Tanmaya Desai | Dharmesh Kakkad |
Start Date | 17 May 2024 | 23 Feb 2021 |
Name
Start Date
Description | The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 04 Jun 1999 | 25 Jun 2018 |
Description
Launch Date